Last reviewed · How we verify

ethinyl estradiol/etonogestrel vaginal ring — Competitive Intelligence Brief

ethinyl estradiol/etonogestrel vaginal ring (ethinyl estradiol/etonogestrel vaginal ring) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined hormonal contraceptive. Area: Contraception / Reproductive Health.

marketed Combined hormonal contraceptive Estrogen receptor and progesterone receptor Contraception / Reproductive Health Small molecule Live · refreshed every 30 min

Target snapshot

ethinyl estradiol/etonogestrel vaginal ring (ethinyl estradiol/etonogestrel vaginal ring) — University of Pittsburgh. Ethinyl estradiol and etonogestrel work together as a combined hormonal contraceptive that suppresses ovulation and alters cervical mucus to prevent pregnancy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ethinyl estradiol/etonogestrel vaginal ring TARGET ethinyl estradiol/etonogestrel vaginal ring University of Pittsburgh marketed Combined hormonal contraceptive Estrogen receptor and progesterone receptor
Ethinyl Estradiol / Norgestimate Oral Tablet Ethinyl Estradiol / Norgestimate Oral Tablet University of Colorado, Denver marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor and progesterone receptor
ethinyl estradiol/norelgestromin transdermal contraceptive ethinyl estradiol/norelgestromin transdermal contraceptive University of Pittsburgh marketed Hormonal contraceptive Estrogen receptor and progesterone receptor
Estradiol valerate / dienogest Estradiol valerate / dienogest Helsinki University Central Hospital marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor and progesterone receptor
ETHINYL ESTRADIOL AND LEVOGESTREL ETHINYL ESTRADIOL AND LEVOGESTREL FHI 360 marketed Combined oral contraceptive Estrogen receptor and progesterone receptor
OCR OCR Hoffmann-La Roche marketed Combined oral contraceptive Estrogen receptor and progesterone receptor
placebo + ethinylestradiol/levonorgestrel placebo + ethinylestradiol/levonorgestrel HRA Pharma marketed Combined oral contraceptive Estrogen receptor and progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined hormonal contraceptive class)

  1. Andrea Roe, MD, MPH · 1 drug in this class
  2. Organon and Co · 1 drug in this class
  3. University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ethinyl estradiol/etonogestrel vaginal ring — Competitive Intelligence Brief. https://druglandscape.com/ci/ethinyl-estradiol-etonogestrel-vaginal-ring. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: